Manufacturers of branded drugs covered by Medicare Part D would need to lower list prices by 28% to 45% to ensure program stability if rebates are no longer allowed, Humana Inc. told HHS in recent comments.
“Removing rebates from the system without negatively impacting the Medicare program and beneficiaries will require drug prices to decrease substantially...






